glucarpidase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	5138	9074-87-7

Description:

Molecule	Description
Synonyms: glucarpidase voraxaze megludase glucarpidase (genetical recombination)	a recombinant bacterial enzyme that hydrolyzes the carboxylterminal glutamate residue from folic acid and classical antifolates such as methotrexate, provides an alternate non-renal pathway for methotrexate elimination in patients with renal dysfunction during high-dose methotrexate treatment Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

glucarpidase
voraxaze
megludase
glucarpidase (genetical recombination)

a recombinant bacterial enzyme that hydrolyzes the carboxylterminal glutamate residue from folic acid and classical antifolates such as methotrexate, provides an alternate non-renal pathway for methotrexate elimination in patients with renal dysfunction during high-dose methotrexate treatment

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
Jan. 11, 2022	EMA	SERB SAS
Jan. 17, 2012	FDA	BTG INTERNATIONAL INC
Sept. 27, 2021	PMDA	OHARA PHARMACEUTICAL CO., LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Laboratory test interference	115.43	91.89	14	126	632	63488250

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Laboratory test interference	129.09	94.54	17	221	463	34956230

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Laboratory test interference	226.56	94.45	30	370	1171	79742817
False positive investigation result	95.85	94.45	14	386	1098	79742890

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AF09	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment
FDA CS	M0003411	Carboxypeptidases
FDA EPC	N0000184013	Carboxypeptidase

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Toxic plasma methotrexate concentration reduction	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
2GFP9BJD79	UNII
4031567	VANDF
C0007072	UMLSCUI
CHEMBL1863515	ChEMBL_ID
D10260	KEGG_DRUG
21195079	PUBCHEM_CID
DB08898	DRUGBANK_ID
8509	INN_ID
7450	IUPHAR_LIGAND_ID
1242127	RXNORM
186910	MMSL
27039	MMSL
d07583	MMSL
014126	NDDF
130594006	SNOMEDCT_US
716225006	SNOMEDCT_US
763579008	SNOMEDCT_US
C000629556	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Voraxaze	HUMAN PRESCRIPTION DRUG LABEL	1	50633-210	INJECTION, POWDER, FOR SOLUTION	1000 [USPU]	INTRAVENOUS	BLA	24 sections
Voraxaze	HUMAN PRESCRIPTION DRUG LABEL	1	50633-210	INJECTION, POWDER, FOR SOLUTION	1000 [USPU]	INTRAVENOUS	BLA	24 sections